Effect of alpha-tocopherol on LDL oxidation and glycation: in vitro and in vivo studies.
Much data support a role for both low density lipoprotein (LDL) oxidation and glycation in atherogenesis. While alpha-tocopherol decreases the oxidative susceptibility of LDL, its role in decreasing LDL glycation is unclear. Hence we tested the effect of alpha-tocopherol both in vitro and in vivo on LDL oxidation and glycation. LDL was isolated after enrichment of plasma with alpha-tocopherol. This resulted in a 2-fold increase in alpha-tocopherol in LDL (AT-LDL). During a 6-day incubation of control LDL (C-LDL) and AT-LDL with 25 mM glucose, there were no significant differences in the degree of glycation on days 1, 3, and 6. Also, apoB advanced glycosylation end product levels were not significantly different between C-LDL and AT-LDL. There was a progressive increase in the susceptibility of LDL to oxidation with increasing LDL glycation as evidenced by reduced lag time of copper-catalyzed LDL oxidation. However, AT-LDL was more resistant to copper-catalyzed oxidation. Similar findings were observed when the LDLs were incubated with endothelial cells. The data from the alpha-tocopherol supplementation study confirmed our in vitro findings that alpha-tocopherol significantly decreases oxidative susceptibility of LDL, but does not affect its glycation. Therefore, while glycation increases LDL oxidative susceptibility, alpha-tocopherol decreases the oxidation of glycated LDL but not LDL glycation.
Li
D
D
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235, USA.
Devaraj
S
S
Fuller
C
C
Bucala
R
R
Jialal
I
I
D001161:Arteriosclerosis / Q000209:etiology; D003300:Copper / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000378:metabolism; D005260:Female; D005947:Glucose / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D010084:Oxidation-Reduction / Q000187:drug effects; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D014810:Vitamin E / Q000494:pharmacology*
D017127:Glycation End Products, Advanced; D008077:Lipoproteins, LDL; D017392:Thiobarbituric Acid Reactive Substances; D014810:Vitamin E; D003300:Copper; D005947:Glucose